SOURCE-LINKED STUDY SUMMARY
Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.
Abstract summarizedQuality not appraised
- What was studied
- Tirzepatide for high blood glucose that developed during pasireotide treatment for a hormone-producing pituitary tumor.
- Who / model studied
- One 48-year-old woman treated with pasireotide after pituitary surgery. Sitagliptin and oral semaglutide had not adequately controlled her glucose. Follow-up duration is not given in the abstract.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- After switching to tirzepatide, HbA1c, a measure of average blood sugar, fell from 7.7% to 6.3%, and random glucose measurements also improved.
- Limitations & context
- A single case cannot establish comparative effectiveness. The authors call for studies comparing the result with intensified GLP-1 therapy.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1507/endocrj.ej26-0396